1. No better solution for antipsychotic treatment with regard to long-term safety and effectiveness
- Author
-
Yea Huei K.ao Yang and Edward Chia Cheng Lai
- Subjects
Male ,Dibenzothiazepines ,medicine.medical_specialty ,Neurology ,Quinolones ,Antipsychotic treatment ,Piperazines ,Article ,law.invention ,Benzodiazepines ,law ,Epidemiology ,medicine ,Humans ,Intensive care medicine ,Psychiatry ,Clinical pharmacology ,business.industry ,Risperidone ,medicine.disease ,Psychiatry and Mental health ,Psychotic Disorders ,Schizophrenia ,Female ,Observational study ,Metabolic syndrome ,medicine.symptom ,business ,Weight gain ,Antipsychotic Agents - Abstract
Using various end points, the comparative effectiveness and safety of antipsychotics in patients with schizophrenia and other psychiatric indications have been demonstrated by a number of experimental and observational studies.1 While atypical antipsychotics (AAPs) are indicated more frequently and extensively, their long-term safety in older patients, including the risk of weight gain, metabolic syndrome, cardiovascular and cerebrovascular events, has been a growing concern.2
- Published
- 2014